Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.
2.

Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.

Berger A, Edelsberg J, Bollu V, Alvir JM, Dugar A, Joshi AV, Oster G.

BMC Psychiatry. 2011 Dec 12;11:193. doi: 10.1186/1471-244X-11-193.

3.

A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.

Carrasco JL, Álvarez E, Olivares JM, Rejas J.

Actas Esp Psiquiatr. 2013 May-Jun;41(3):164-74. Epub 2013 May 1.

4.

Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden.

Sandelin R, Kowalski J, Ahnemark E, Allgulander C.

Eur Psychiatry. 2013 Feb;28(2):125-33. doi: 10.1016/j.eurpsy.2012.02.003. Epub 2012 Apr 26.

PMID:
22542328
5.

WCA recommendations for the long-term treatment of generalized anxiety disorder.

Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP; World Council of Anxiety.

CNS Spectr. 2003 Aug;8(8 Suppl 1):53-61. Review.

PMID:
14767398
6.

Reimbursement restriction and moderate decrease in benzodiazepine use in general practice.

Hoebert JM, Souverein PC, Mantel-Teeuwisse AK, Leufkens HG, van Dijk L.

Ann Fam Med. 2012 Jan-Feb;10(1):42-9. doi: 10.1370/afm.1319.

7.

Treatment of generalized anxiety disorder.

Gorman JM.

J Clin Psychiatry. 2002;63 Suppl 8:17-23. Review.

8.

Comorbidities and associated treatment charges in patients with anxiety disorders.

McLaughlin T, Geissler EC, Wan GJ.

Pharmacotherapy. 2003 Oct;23(10):1251-6.

PMID:
14594343
9.
10.

Generalized anxiety disorder: raising the expectations of treatment.

Allgulander C, Sheehan DV.

Psychopharmacol Bull. 2002 Summer;36 Suppl 2:68-78. Review.

PMID:
17450651
11.

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP.

Am J Manag Care. 2005 Oct;11(12 Suppl):S354-61.

12.

Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.

Panzer PE, Regan TS, Chiao E, Sarnes MW.

Am J Manag Care. 2005 Oct;11(12 Suppl):S370-9.

13.

Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.

Bereza BG, Machado M, Einarson TR.

Clin Ther. 2009 Jun;31(6):1279-308. doi: 10.1016/j.clinthera.2009.06.004. Review.

PMID:
19695395
14.

A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder.

Czobor P, Skolnick P, Beer B, Lippa A.

CNS Neurosci Ther. 2010 Apr;16(2):63-75. doi: 10.1111/j.1755-5949.2009.00109.x. Epub 2009 Dec 22.

PMID:
20041911
15.

Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder.

DeMartinis N, Rynn M, Rickels K, Mandos L.

J Clin Psychiatry. 2000 Feb;61(2):91-4.

PMID:
10732655
16.

Pharmacotherapy of generalized anxiety disorder.

Rickels K, Rynn M.

J Clin Psychiatry. 2002;63 Suppl 14:9-16. Review.

17.

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, Dow MG, Gumley AI.

Health Technol Assess. 2005 Nov;9(42):1-174. Review.

18.

The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.

Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E, Cabasés JM.

Community Ment Health J. 2012 Jun;48(3):372-83. doi: 10.1007/s10597-012-9503-4. Epub 2012 Apr 8.

PMID:
22484993
19.

[Anxiety and depressive disorders in 4,425 long term benzodiazepine users in general practice].

Pélissolo A, Maniere F, Boutges B, Allouche M, Richard-Berthe C, Corruble E.

Encephale. 2007 Jan-Feb;33(1):32-8. French.

PMID:
17457292
20.

Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.

Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G.

BMC Pulm Med. 2012 Dec 11;12:75. doi: 10.1186/1471-2466-12-75.

Supplemental Content

Support Center